Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy


Abstract

PEGylated nanoparticles and macromolecules are increasingly used in cancer imaging and anticancer treatment. The role of receptor-mediated endocytosis in the efficacy of these agents, however, has not been clearly defined. Here, we developed a matched pair of endocytic and nonendocytic receptors to directly and unambiguously assess this issue. The ligand-binding domains of the low-density lipoprotein receptor (LDLR) or a truncated LDLR lacking the NPXY endocytosis motif (ΔLDLR) were replaced with an anti–polyethylene glycol antibody (αPEG) to form endocytic αPEG-LDLR and nonendocytic αPEG-ΔLDLR receptors. The receptors were stably expressed at similar levels on the surface of HCC36 cells. HCC36/αPEG-LDLR cells, but not HCC36/αPEG-ΔLDLR cells, rapidly endocytosed PEG-quantum dots and PEG-liposomal doxorubicin (Lipo-Dox) in vitro and in vivo. Lipo-Dox was significantly more cytotoxic to HCC36/αPEG-LDLR cells than to HCC36/αPEG-ΔLDLR cells. HCC36/αPEG-LDLR tumors also accumulated significantly more PEGylated near-IR probes (PEG-NIR797) and PEG-liposomal doxorubicin (PEG-LDLR) were replaced with an anti–polyethylene glycol antibody (αPEG) to form endocytic αPEG-LDLR and nonendocytic αPEG-ΔLDLR tumors in vitro. Furthermore, Lipo-Dox more significantly suppressed the growth of established HCC36/αPEG-LDLR tumors as compared with HCC36/αPEG-ΔLDLR tumors. Our data show that endocytosis of PEGylated probes and drugs enhances both cancer imaging and anticancer efficacy, indicating that endocytic receptors are superior targets for the design of cancer imaging probes and immunoliposomal drugs. Mol Cancer Ther; 9(6); 1903–12. ©2010 AACR.

Introduction

Extensive efforts are under way to develop nanoparticles, macromolecules, and proteins that can selectively accumulate in the tumor microenvironment for improved detection and treatment of cancer. Polyethylene glycol (PEG), a flexible polymer, is often covalently attached to these agents to reduce unintended uptake by normal tissues, decrease systemic toxicity, prolong circulation time in the blood, and enhance tumor accumulation (1–5). A prominent example of a PEGylated nanoparticle is PEG-liposomal doxorubicin (Lipo-Dox), which has been approved by the Food and Drug Administration for clinical treatment of ovarian and breast carcinomas and Kaposi’s sarcoma (6, 7). Tumor-binding ligands such as peptides (8, 9) and antibodies (10, 11) may be conjugated to the distal terminus of PEGylated nanoparticles and macromolecules to increase targeting specificity. Thus far, various tumor-associated antigens or receptors have been validated as targets for PEGylated compounds, especially for immunoliposomes (10–15). These tumor-associated antigens or receptors can be either endocytic or nonendocytic.

Although PEGylated nanoparticles such as immunoliposomes have shown good clinical activity and promising results in experimental cancer models, it is still unclear how much endocytosis contributes to their anticancer activity. For example, some studies indicate that liposomal drugs targeted to noninternalizing markers facilitate release of drug near the cell surface over time, resulting in bystander toxicity to nearby tumor cells (16, 17). However, the diffusion and redistribution of released drug away from the tumor site may be faster than the speed of drug entry into tumor cells, thus decreasing...
treatment efficiency (18, 19). Other experimental evidence supports the hypothesis that targeting immunoliposomes to endocytic receptors results in better delivery of anticancer agents into cancer cells for enhanced therapeutic efficacy (10–13). Improved treatment efficiency was largely attributed to enhanced cellular internalization of drugs rather than to increased accumulation in tumors (20, 21). Although most experimental results tend to support a role for receptor-mediated endocytosis in the anticancer efficacy of nanoparticles, previous studies have lacked a complementary control (a nonendocytic receptor) and may not provide direct and unbiased evidence to prove this hypothesis. Likewise, it remains unclear whether endocytosis of imaging probes can increase tumor accumulation and detection sensitivity (22–26).

In this report, we sought to (a) develop universal cell-surface receptors for PEGylated molecules and (b) directly address whether receptor-mediated endocytosis can enhance the accumulation and efficacy of PEGylated imaging and therapeutic agents. We describe a matched pair of endocytic and nonendocytic anti-PEG receptors in which a novel anti-PEG antibody was fused to a truncated low-density lipoprotein receptor (LDLR) (refs. 27, 28; Fig. 1A). Expression of these universal anti-PEG receptors on HCC36 hepatocellular carcinoma cells allowed us to unambiguously begin to define the role of endocytosis in the in vitro and in vivo efficacy of PEGylated imaging and therapeutic compounds.
Materials and Methods

Materials and reagents
Lipo-Dox was purchased from Taiwan Tung Yang Biopharm Company Ltd. Lipo-Dox contains 2 mg/mL doxorubicin and 14 mol/mL phospholipids. Its lipid composition is DSPC, cholesterol, and PEG-DSPE (molar ratio 3:2:0.3). Lipo-Dox has an average particle size of 104.2 ± 28.3 nm as described previously (29). The synthesis of PEG-liposomal-111In (Lipo-111In) has been described (30). Lipo-111In has the same lipid composition and similar particle size as Lipo-Dox.

Cells and animals
Human HCC36 hepatocellular carcinoma cells (American Type Culture Collection) were cultured in DMEM (Sigma-Aldrich) supplemented with 10% heat-inactivated bovine calf serum, 100 units/mL penicillin, and 100 μg/mL streptomycin at 37°C in an atmosphere of 5% CO2. Specific pathogen-free female BALB/c nude mice were obtained from the National Laboratory Animal Center, Taipei, Taiwan. All animal experiments were done in accordance with institutional guidelines and approved by the Animal Care and Use Committee of the Kaohsiung Medical University.

Construction and transduction of the endocytic αPEG-LDLR and the nonendocytic αPEG-ΔLDLR receptors
The V1-Cκ and V1f-C11 domains of an anti-PEG IgM monoclonal antibody (αPEG) were cloned from cDNA prepared from the AGP3 hybridoma (31) following a previously described method (32). Primers used in the cloning of V1-Cκ and V1f-C11 are as follows: sense V1-Cκ, 5′-tgctggggccagacggctgctctgcttgtg-3′; antisense V1-Cκ, 5′-ccgctcgagacactcattcctgttgaagct-3′; sense V1f-C11, 5′-ggatcctgcagactcattcctgttgaagct-3′; sense V1f-C11, 5′-ccgctcgagacactcattcctgttgaagct-3′; antisense V1f-C11, 5′-ccgctcgagacactcattcctgttgaagct-3′.
The V1-Cκ and V1f-C11 genes were joined by an internal ribosomal entry site and fused to the C-like extracellular, transmembrane, and cytosolic domains of the human LDLR or a truncated LDLR (ΔLDLR) lacking the NPYX signal motif to form αPEG-LDLR and αPEG-ΔLDLR, respectively. The αPEG-LDLR and αPEG-ΔLDLR sequences were then inserted into the pLNCX retroviral vector (Clontech), using the SfiI and ClaI restriction sites, to generate pLNCX-αPEG-LDLR and pLNCX-αPEG-ΔLDLR, respectively. Recombinant retroviral particles were produced by cotransfection of pSVG with pLNCX-αPEG-LDLR or pLNCX-αPEG-ΔLDLR into GP2-293 cells (Clontech, BD Biosciences) with Lipofectamine 2000 (Invitrogen). After 48 hours, the culture medium was filtered, mixed with 8 μg/mL polybrene (Sigma-Aldrich), and added to HCC36 cells. Following retroviral transduction for 48 hours, the cells were selected in G418 and sorted on a flow cytometer to generate HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR cells that expressed approximately equal levels of αPEG-LDLR or αPEG-ΔLDLR receptors.

Western blotting analysis
HCC36, HCC36/αPEG-LDLR, and HCC36/αPEG-ΔLDLR cells (5 × 104) were washed in PBS and heated in reducing sample buffer at 100°C for 10 minutes. The samples were electrophoresed in an 8% SDS polyacrylamide gel under reducing conditions and then transferred onto a nitrocellulose paper (Millipore). After blocking in 5% skim milk, the membrane was incubated sequentially with 1 μg/mL horseradish peroxidase-conjugated goat anti-mouse IgG μ-chain antibody (Jackson ImmunoResearch Laboratories). The blots were washed three times with PBS-T (PBS containing 0.05% Tween 20) and twice with PBS before specific bands were visualized by enhanced chemiluminescence detection according to the manufacturer’s instructions (Pierce).

Flow cytometric analysis
Surface expression of the receptors was measured by staining cells with 1 μg/mL mouse anti-HA antibody, followed by 1 μg/mL FITC-conjugated goat anti-mouse IgG (Fc) (Jackson ImmunoResearch Laboratories) in PBS containing 0.05% bovine serum albumin on ice. Functional PEG binding activity of the receptors was determined by incubating the cells with 4 μmol/L PEG-quantum dot 525 (Invitrogen) in PBS containing 0.05% bovine serum albumin on ice. After removing unbound PEG-quantum dots (PEG-QD) by extensive washing in cold PBS, the surface immunofluorescence of viable cells was measured on a FACScalibur flow cytometer (BD Biosciences) and analyzed with FlowJo V3.2 (Tree Star, Inc.)

In vitro cytotoxicity
HCC36, HCC36/αPEG-LDLR, and HCC36/αPEG-ΔLDLR cells (103 per well) were seeded overnight in 96-well microtiter plates. Graded concentrations of Lipo-Dox (Schering-Plough) or doxorubicin were added to the cells in triplicate at 37°C for 6 or 24 hours. The cells were subsequently washed and incubated for an additional 48 hours in fresh culture medium. Cell viability was determined with the ATPlite assay kit following the manufacturer’s instructions (Perkin-Elmer Life and Analytical Sciences). Results are expressed as percent inhibition of luminescence as compared with untreated cells by the following formula: % inhibition = 100 × (sample luminescence − background luminescence)/control luminescence − background luminescence).

Imaging of receptor-mediated endocytosis by confocal microscopy
HCC36/αPEG-LDLR or HCC36/αPEG-ΔLDLR cells were incubated with 10 nmol/L PEG-QDs or 2 mg/mL Lipo-Dox in DMEM containing 10% bovine calf serum at 37°C for 3 minutes. After extensive washing, Lipo-Dox–stained cells were incubated with FITC-conjugated AGP3 antibody (2 μg/mL) in DMEM containing 10% bovine calf serum at 37°C for 3 minutes.
After extensive washing, the endocytic activity of the receptors was recorded in real time with a confocal microscope (Axiovert 200, Carl Zeiss, Inc.). To image receptor-mediated endocytosis in vivo, BALB/c nude mice bearing HCC36, HCC36/αPEG-LDLR, and HCC36/αPEG-ΔLDLR tumors (∼100 mm³) in their dorsal and right and left hind leg regions, respectively, were intratumorally injected with 16 pmol of PEG-QDs (n = 3) or were i.v. injected with 10 mg/kg body weight of Lipo-Dox (n = 3). Mice were killed and tumors were harvested at 4 hours after injection. After extensive washing in PBS, the endocytic activity of the receptors was observed by two-photon confocal microscopy (LSM 510 META NLO Duoscan, Carl Zeiss).

**Synthesis of PEG-NIR797**

CH₂₃-PEG₃₀₀₀₀-NH₂ (Sigma) was reacted with NIR797-isothiocyanate (Sigma) at a molar ratio of 1:2 in DMF containing 0.1% triethylamine at room temperature for 1 hour. The presence of the NIR797 group was verified by UV detection, whereas primary amine groups were detected by reaction with ninhydrin/2% solution (Sigma). The reaction mixture was separated on silica gel with dichloromethane-methanol (8:2, v/v) to obtain expected sizes of 58 and 54 kDa, respectively (Fig. 1B). Western blot analysis showed that the cells expressed the LDLR, and a truncated LDLR (ΔLDLR) lacking the NPXY signal motif for endocytosis (27). HCC36 hepatocellular carcinoma cells were infected with recombinant retroviral particles and selected in G418 to obtain HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR cells. Western blot analysis showed that the cells expressed αPEG-LDLR and αPEG-ΔLDLR receptors with the expected sizes of 58 and 54 kDa, respectively (Fig. 1B). The surface expression of the receptors was analyzed by two-photon confocal microscopy. Surface display of functional αPEG receptors (Fig. 1A) encode chimeric proteins in which an anti-PEG Fab fragment was fused to the C-like extracellular, transmembrane, and cytosolic domains of LDLR or a truncated LDLR (ΔLDLR) lacking the NPXY signal motif for endocytosis (27). HCC36 hepatocellular carcinoma cells were infected with recombinant retroviral particles and selected in G418 to obtain HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR cells. Western blot analysis showed that the cells expressed αPEG-LDLR and αPEG-ΔLDLR receptors with the expected sizes of 58 and 54 kDa, respectively (Fig. 1B). The surface expression of the receptors was analyzed by immunofluorescence staining using a specific anti-PEG Fab fragment to the HA epitope present at the NH₂ terminus of the receptors. Figure 1C shows that similar levels of αPEG-LDLR and αPEG-ΔLDLR receptors were expressed on HCC36 cells. To confirm the PEG binding activity of the receptors, we stained the cells with PEG-QDs. Both receptors displayed comparable PEG-binding activity.

**In vivo optical imaging**

BALB/c nude mice (n = 5) bearing HCC36, HCC36/αPEG-LDLR, and HCC36/αPEG-ΔLDLR tumors (∼100 mm³) in their dorsal and right and left hind leg regions, respectively, were i.v. injected with 10 mg/kg body weight of Lipo-Dox or PBS once a week for 3 weeks. Treatment efficacy was monitored by measuring tumor volumes (length × width × height × 0.5) on a weekly basis.

**Data analysis**

The cytotoxicity of Lipo-Dox was compared by one-way ANOVA using Instat software (GraphPad Software version 3.0, GraphPad Software) with significance determined by the Student t test. In vivo uptake of PEG-QDs by cells was numerated from confocal microscopic images and analyzed by the Student t test. Tumor uptake of PEGylated molecules, biodistribution of Lipo-¹¹¹In, and therapeutic efficacies among groups were compared by the Wilcoxon rank-sum test after the Kruskal-Wallis test. Bonferroni correction was used to adjust significance level for multiple (3) comparisons. P value ≤ Bonferroni corrected significance level (0.05/3 = 0.0167) was considered significant.

**Results**

**Surface display of functional αPEG receptors**

The retroviral vectors pLNCX-αPEG-LDLR and pLNCX-αPEG-ΔLDLR (Fig. 1A) encode chimeric proteins in which an anti-PEG Fab fragment was fused to the C-like extracellular, transmembrane, and cytosolic domains of LDLR or a truncated LDLR (ΔLDLR) lacking the NPXY signal motif for endocytosis (27). HCC36 hepatocellular carcinoma cells were infected with recombinant retroviral particles and selected in G418 to obtain HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR cells. Western blot analysis showed that the cells expressed αPEG-LDLR and αPEG-ΔLDLR receptors with the expected sizes of 58 and 54 kDa, respectively (Fig. 1B). The surface expression of the receptors was analyzed by immunofluorescence staining using a specific antibody to the HA epitope present at the NH₂ terminus of the receptors. Figure 1C shows that similar levels of αPEG-LDLR and αPEG-ΔLDLR receptors were expressed on HCC36 cells. To confirm the PEG binding activity of the receptors, we stained the cells with PEG-QDs. Both receptors displayed comparable PEG-binding activity.
activity (Fig. 1D). These results indicate that the receptors were expressed at similar levels and retained equivalent PEG-binding activities on HCC36 cells.

**In vitro and in vivo endocytic activities of αPEG receptors**

To compare the endocytic activities of the receptors, live HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR cells were stained with PEG-QDs and then examined under a confocal microscope in real time. HCC36/αPEG-LDLR cells displayed more green fluorescence within endocytic vesicles than did HCC36/αPEG-ΔLDLR cells after PEG-QDs staining (Fig. 2A, movie available as Supplementary Material 1). On average, green fluorescent endocytic vesicles per cell were 27.3-fold (10.3 versus 0.38, \( P = 0.0004 \)), 9.3-fold (15.1 versus 1.63, \( P = 0.0003 \)), and 9.1-fold (17.1 versus 1.88, \( P = 0.0005 \)) more in HCC36/αPEG-LDLR cells than in HCC36/αPEG-ΔLDLR cells at 600, 900, and 1,200 seconds after incubation of PEG-QDs, respectively. These results show that a matched pair of cells expressing endocytic and nonendocytic anti-PEG receptors was successfully established. These cells were next incubated with Lipo-Dox and then stained with a FITC-conjugated anti-PEG antibody to detect the cellular location of Lipo-Dox. Figure 2B shows that doxorubicin (red fluorescence) and PEG-liposomes (green fluorescence) colocalized within the cytoplasm of HCC36/αPEG-LDLR cells to a greater extent than in HCC36/αPEG-ΔLDLR cells, indicating that Lipo-Dox was indeed endocytosed via αPEG-LDLR receptors (movie available as Supplementary Material 2). Although we noted some doxorubicin (red fluorescence) within HCC36/αPEG-ΔLDLR cells (Fig. 2B, bottom), this doxorubicin did not colocalize with the...
PEG-liposomes (green fluorescence), suggesting that some doxorubicin may have entered the cells by diffusion. In addition, the difference in endocytic activity between αPEG-LDLR and αPEG-ΔLDLR receptors was also obvious in vivo as determined by two-photon confocal microscopy. Figure 3A shows that PEG-QDs accumulated intracellularly in the endocytic vesicles of HCC36/αPEG-LDLR tumors but not in HCC36/αPEG-ΔLDLR and HCC36 tumors. Similar results were also observed for the endocytosis of Lipo-Dox in vivo (Fig. 3B). Thus, the endocytic activity of the αPEG-LDLR receptor clearly exceeds that of the αPEG-ΔLDLR receptor in vivo. Collectively, these data show that endocytosis of imaging probes and therapeutic agents enhances their intracellular accumulation in vitro and in vivo.

**Endocytosis enhances Lipo-Dox cytotoxicity**

Lipo-Dox is now used as a preferred anticancer drug because free-form doxorubicin can produce severe cardiac toxicity (33–35). To determine whether targeting Lipo-Dox to endocytic or nonendocytic receptors would lead to differential cytotoxicity, HCC36, HCC36/αPEG-LDLR, and HCC36/αPEG-ΔLDLR cells were incubated with Lipo-Dox or free doxorubicin for 6 or 24 hours. The viability of the cells after drug treatment was determined by quantification of cellular ATP synthesis. IC_{50} values of free doxorubicin to HCC36/αPEG-LDLR, HCC36/αPEG-ΔLDLR, and HCC36 cells were 4.8, 4.2, and 3.4 μg/mL for 6-hour treatment and 0.6, 0.65, and 0.8 μg/mL for 24-hour treatment, indicating that all three cell lines displayed similar sensitivities to free doxorubicin (Fig. 4A and B). By contrast, HCC36/αPEG-LDLR cells were more sensitive to Lipo-Dox (IC_{50} = 15.5 μg/mL) than were HCC36/αPEG-ΔLDLR (IC_{50} > 54 μg/mL, P = 0.0002) or HCC36 cells (IC_{50} > 54 μg/mL, P < 0.0001) at 6-hour treatment.

Treatment of HCC36/αPEG-LDLR cells with Lipo-Dox for 24 hours also caused more pronounced cytotoxicity (IC_{50} = 3.7 μg/mL) as compared with HCC36/αPEG-ΔLDLR cells (IC_{50} = 46.5 μg/mL, P = 0.0003) and HCC36 cells (IC_{50} > 54 μg/mL, P < 0.0001). In addition, similar results were also observed in a human MCF-7 breast tumor model (Supplementary Fig. S1). These data clearly show that targeting Lipo-Dox to endocytic αPEG-LDLR receptors enhances anticancer activity in vivo. On the other hand, addition of PEG-liposomes that do not contain doxorubicin did not induce noticeable cell death or proliferation (Supplementary Fig. S2), excluding the possibility that the presence of the NPXY motif may transduce survival-related signals.

**Targeting endocytic receptors enhances cancer imaging in vivo**

To test whether endocytosis affects imaging in vivo, BALB/c nude mice bearing established HCC36/αPEG-LDLR, HCC36/αPEG-ΔLDLR, and HCC36 tumors were injected with a PEGylated near-IR probe (PEG-NIR797) or Lipo^{111}In. Whole-body images of the tumor-bearing mice were acquired by optical or gamma camera imaging, respectively, at 24, 48, and 72 hours. Figure 5A shows that, after 24 hours, HCC36/αPEG-LDLR tumors displayed more conspicuous fluorescence than did HCC36/αPEG-ΔLDLR and HCC36 tumors. Fluorescent intensities in the region of interest for HCC36/αPEG-LDLR tumors were 1.01- to 1.24-fold greater at 24 hours, 1.08- to 2.02-fold greater at 48 hours, and 1.2- to 3.54-fold greater at 72 hours than HCC36/αPEG-ΔLDLR tumors (P < 0.009, comparing HCC36/αPEG-LDLR with HCC36/αPEG-ΔLDLR at 48 and 72 hours), respectively (Fig. 5B). Similar results were observed for Lipo^{111}In (Fig. 5C). Radioactivity in HCC36/αPEG-LDLR tumors...
was 1.02- to 1.42-fold greater at 24 hours, 1.32- to 2.15-fold greater at 48 hours, and 1.4- to 3.9-fold greater at 72 hours than HCC36/αPEG-ΔLDLR tumors (P < 0.0163, comparing HCC36/αPEG-LDLR with HCC36/αPEG-ΔLDLR at 48 and 72 hours), respectively (Fig. 5D). These results show that targeting PEGylated probes or liposome to endocytic receptors can significantly enhance accumulation in tumors and improve detection sensitivity.

**Targeting endocytic receptors enhances the anticancer efficacy of Lipo-Dox**

To directly test the importance of receptor-mediated endocytosis of Lipo-Dox in cancer treatment, BALB/c nude mice bearing HCC36, HCC36/αPEG-LDLR, or HCC36/αPEG-ΔLDLR tumors were treated with Lipo-Dox or PBS. Tumor volumes were monitored as an indicator of Lipo-Dox efficacy. Overall, Lipo-Dox better suppressed the growth of HCC36/αPEG-LDLR tumors (Fig. 6A and B) and did not cause critical side effects (weight losses) in mice during the course of treatment (data not shown). Treating tumor-bearing mice with 2.5 mg/kg body weight of Lipo-Dox resulted in borderline differences between HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR tumors (471.5 ± 111.7 versus 1,222.5 ± 319.2 mm$^3$ on day 63, P = 0.043; Bonferroni-corrected P = 0.0167). When mice were treated with 5 mg/kg Lipo-Dox, HCC36/αPEG-LDLR tumors were significantly suppressed at day 63 as compared with HCC36/αPEG-ΔLDLR tumors (63.2 ± 23.2 versus 830.4 ± 241.4 mm$^3$, P = 0.0062; Fig. 6B). Thus, our data show that targeting endocytic receptors can indeed enhance the therapeutic efficacy of Lipo-Dox in vivo.

**Discussion**

By creating a matched pair of endocytic and nonendocytic receptors with specificity for any PEGylated compound, we directly and unambiguously assessed the role of endocytosis in determining the efficacy of PEGylated molecules and nanoparticles for cancer imaging and therapy. Endocytic αPEG receptors significantly increased the accumulation of PEGylated imaging probes and Lipo-Dox within tumor cells as compared with nonendocytic αPEG receptors. We observed increased accumulation of PEG-NIR797 and Lipo-111In in tumors expressing endocytic αPEG receptors, which translated to stronger imaging intensity. Targeting endocytic receptors on cancer cells also significantly improved the therapeutic efficacy of Lipo-Dox both in vitro and in vivo. Thus, our study provides strong evidence that endocytosis of PEGylated imaging probes and liposomes enhances their biological activities.

The contribution of endocytosis to the efficacy of liposomal drugs has been controversial. For example, Park et al. (10) proposed that the improved anticancer efficacy of immunoliposomes was due to increased cellular internalization rather than to enhanced accumulation of liposomes at tumor sites. Sapra and Allen (20) showed that targeting immunoliposomes to internalizing CD19 molecules attained a higher therapeutic index than targeting to noninternalizing CD20 molecules on B-lymphoma cells. However, because B cells do not express similar amounts of CD19 and CD20, the relative contributions of dosage versus internalization are difficult to discern. Furthermore, on ligation with immunoliposomes, CD19 and CD20 can transduce distinct signals through different downstream effectors, which may further confound interpretation of treatment efficacies (36–39). It is therefore difficult to precisely assign the relative contribution of endocytosis in immunoliposome efficacy when using different tumor markers. To directly address this issue, we expressed on HCC36 cells endocytic or nonendocytic αPEG receptors with identical specificity. By expressing similar levels of the
receptors on cells, possible dose-related effects were avoided. Consistent with other receptors (28, 40, 41), the NPXY signal motif in the LDLR did not transduce survival-related signals after the receptors were cross-linked with PEGylated compounds. This model therefore represents an unbiased system to analyze the importance of endocytosis of Lipo-Dox in tumor therapy. By using this model, we show here that endocytosis of Lipo-Dox augments treatment efficacy.

Enhanced treatment efficacy toward HCC36 cancer cells expressing endocytic αPEG receptors is consistent with our in vitro and in vivo imaging studies. As shown in confocal microscopic studies, significantly more endosomes containing Lipo-Dox and PEG-QDs were observed in HCC36/αPEG-LDLR cells. Because HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR initially bound similar amounts of Lipo-Dox, and these two cells were equally sensitive to free-form doxorubicin, increased cytotoxicity observed toward HCC36/αPEG-LDLR cells can be attributed to increased accumulation of intracellular Lipo-Dox. Likewise, tracking the accumulation of PEGylated probes in tumors expressing endocytic or nonendocytic αPEG receptors by optical and gamma camera imaging showed stronger signals within HCC36/αPEG-LDLR tumors, which correlated with higher therapeutic index against these tumors after Lipo-Dox treatment.

Our data also indicate that endocytosis of imaging probes enhances detection sensitivity. Signal intensity in HCC36/αPEG-LDLR tumors was significantly greater than that in HCC36/αPEG-ΔLDLR tumor by both optical imaging and gamma camera. In addition, it is interesting that the difference in imaging intensity between the endocytic and the nonendocytic cells was only significant at 48 and 72 hours, but not at 24 hours. This suggests

Figure 5. Targeting endocytic receptors enhances cancer imaging in vivo. A, BALB/c nude mice (n = 5) bearing HCC36 (middle), HCC36/αPEG-LDLR (left hind limb), and HCC36/αPEG-ΔLDLR (right hind limb) tumors were i.v. injected with PEG-NIR797 (5 mg/kg body weight), and images acquired on an IVIS-50 optical imaging system at 24, 48, and 72 h after injection. B, optical intensity in tumors after i.v. injection of PEG-NIR797 was analyzed with Living Image software version 2.50. Points, mean; bars, SEM. C, BALB/c nude mice (n = 7) bearing HCC36 (left shoulder), HCC36/αPEG-LDLR (left hind limb), and HCC36/αPEG-ΔLDLR (right hind limb) tumors were i.v. injected with 80 μCi of Lipo-111In, and images acquired at 24, 48, and 72 h after injection by a gamma camera. D, accumulation of Lipo-111In in tumors by measuring radioactivity of weighted tumors at 24 h (n = 4), 48 h (n = 5), and 72 h (n = 5). Data are expressed as percent injected dose per gram of tissue (%ID/g tissue). * P ≤ 0.0167, between αPEG-LDLR and αPEG-ΔLDLR tumors. n.s., not significant. Columns, mean; bars, SEM.
that both HCC36/αPEG-LDLR and HCC36/αPEG-ΔLDLR tumors can trap PEGylated imaging probes. However, HCC36/αPEG-LDLR tumors are able to internalize the imaging probes, which enhanced the imaging signal over time. Based on these reasons, the stronger signal observed in HCC36/αPEG-LDLR tumors suggests that targeting imaging probes to endocytic tumor markers may aid in detection and diagnosis of smaller tumors in vivo. Moreover, both PEG-NIR797 and Lipo-111 in were endocytosed by the αPEG-LDLR receptor, suggesting that both small-molecule probes and nanoparticles can be conjugated to tumor-targeting ligands for enhanced cancer imaging.

Our observation that endocytosis of imaging probes or liposomal drugs enhances their efficacy may directly affect the future design of more effective imaging probes and anticancer drugs. Based on our data, nanoparticles and macromolecular agents should be designed to target endocytic tumor markers. By combining the benefits of selective targeting and increased intracellular accumulation, this design strategy should produce superior effects over nonendocytic tumor markers.

We provide direct and unbiased in vitro and in vivo evidence that targeted endocytosis of PEG-liposomal drugs and PEG-imaging probes can improve antitumor efficacy and enhance tumor imaging. These results also suggest that future design of immunoliposomes and targeted imaging agents should focus on endocytic epitopes to achieve more effective tumor therapy. Finally, the universal anti-PEG receptors described here may form the basis for genetic marking of tissues to facilitate detection or treatment by any PEGylated compound or nanoparticle.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors acknowledge technical support from the Molecular and Genetic Imaging Core supported by the National Research Program for Genomic Medicine, National Science Council, Taiwan (NSC98-3112-B-037-001), the Scientific Instrument Center of Academia Sinica, the Kaohsiung Medical University Hospital Cancer Center (DOH99-TD-C-111-002), and the National Sun Yat-Sen University-Kaohsiung Medical University Joint Research Center.

**Grant Support**

The National Research Program for Genomic Medicine (NSC98-3112-B-037-001; T.L. Cheng), the National Health Research Institutes (NHRI-EX98-9624SI; T.L. Cheng), and Academia Sinica (AS-98-TP-B09; S.R. Roffler).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/06/2009; revised 03/11/2010; accepted 04/12/2010; published OnlineFirst 05/25/2010.

**References**

6. Hsiao SM, Chen CA, Lin HH, Hsieh CY, Wei LH. Phase II trial of carboplatin and diethyleneamphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer.
following front-line therapy with paclitaxel and platinum. Gynecol Oncol 2009;112:35–9.